Home > Healthcare > Cerebral Spinal Fluid Management Market
Cerebral Spinal Fluid Management Market Size
Cerebral Spinal Fluid Management Market size is projected to grow at a substantial rate from 2024 to 2032. One of the key factors favoring the market outlook is the growing adoption of various tests to analyze a patient’s cerebrospinal fluid (CSF) level to diagnose underlying conditions, such as meningitis and other infectious ailments associated with brain and spinal cord. The rising prevalence of chronic rhinosinusitis with nasal polyps in multiple countries will also stimulate the usage of CSF management devices over the coming years.
According to a report published in NCBI Bookshelf’s StatPearls, in July 2023, the prevalence of hydrocephalus in the elderly surged to approximately 175 per 100,000 and exceeded 400 per 100,000 for individuals aged over 80 years, primarily due to increased occurrence of normal pressure hydrocephalus (NPH) in later life. This rising penetration of hydrocephalus worldwide will positively influence the industry progression. However, high treatment costs, limited accessibility to advanced healthcare in certain regions, and the potential complications associated with surgical interventions for CSF disorders may restrain the industry development to some extent.
Cerebral Spinal Fluid Management Market Trends
In recent years, the episode of chronic health conditions, such as congenital hydrocephalus is significantly rising among infants, further projecting a prominent opportunity for the industry gains. According to data by Johns Hopkins Medicine, 1 or 2 of every 1,000 infants born in the U.S. are affected by congenital hydrocephalus. Likewise, the incidence of brain tumors often linked with the leakage of CSF through the brain covering, is increasing in countries, including the U.K. According to the U.K. NHS, over 11,000 individuals are diagnosed with a primary brain tumor across the country every year.
Cerebral Spinal Fluid Management Market Analysis
Based on product, the market value from the adjustable valve shunts segment is estimated to rise at substantial rate from 2024 to 2032. This is due to rising advancements in adjustable valve technology to offer personalized cerebrospinal fluid regulation. Increasing prevalence of hydrocephalus coupled with the rising geriatric population will fuel the demand for these devices given their enhanced patient outcomes, reduced complications, and improved quality of life.
The WHO projects that 55 million people across the globe currently live with dementia, with over 60% in low- and middle-income countries. By 2030, the number is expected to reach 78 million, and by 2050, it could soar to 139 million due to the rapidly aging population. Given that normal pressure hydrocephalus is a contributor to dementia, this increasing disease burden will favor the adoption for adjustable valve shunt treatment.
Cerebral spinal fluid management market share from the ventriculoperitoneal (VP) shunts type segment is projected to witness expansion through 2032. The growth can be attributed to the rising incidence of hydrocephalus, growing aging population, and the rapid advancements in shunt technology. VP shunts offer effective cerebrospinal fluid diversion and reduce intracranial pressure. The increasing awareness, improved patient outcomes, and the growing demand for minimally invasive neurosurgical interventions will drive the segment expansion.
Regionally, the North America CSF management market is projected to expand at substantial CAGR from 2024 to 2032, owing to the well-established healthcare systems, rising awareness regarding the options for the treatment of hydrocephalus, and the increasing R&D expenditure. The elevated prevalence of neurological conditions, such as strokes, is also anticipated to drive the regional market expansion. For instance, based on the April 2022 report from CDC, over 795,000 individuals in the U.S. undergo a stroke annually, with approximately 610,000 being first or new occurrences.
Cerebral Spinal Fluid Management Market Share
Some of the major cerebral spinal fluid management companies are:
- Sophysa
- Spiegelberg
- Integra LifeSciences
- Medtronic
- DePuy Synthes Companies (Johnson & Johnson)
- Dispomedica (Neuromedex GmbH)
- B. Braun Melsungen
- BeckerSmith Medical
Leading firms in the CSF management industry, such as B. Braun Melsungen and Medtronic among others, are focusing on incorporating corporate strategies, such as forming partnerships, mergers, and acquisitions, and investing in R&D initiatives to sustain market expansion.
Cerebral Spinal Fluid Management Industry News:
- In April 2022, researchers at UTHealth Houston were granted a five-year $2.85 million award from the National Institute of Neurological Disorders and Stroke, a division of the National Institutes of Health (NIH). The funding was aimed to utilize innovative technology in studying infants with hydrocephalus.